Rapid Micro Biosystems (Nasdaq:RPID) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

RPID Stoklara Genel Bakış

RPID temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 24.53% oranında artması öngörülüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( $38M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Rapid Micro Biosystems, Inc. Rakipler

Bioqual

OTCPK:BIOQ

US$60.4m

Champions Oncology

NasdaqCM:CSBR

US$66.2m

Bionano Genomics

NasdaqCM:BNGO

US$39.0m

IsoPlexis

NasdaqGS:ISO

US$30.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Rapid Micro Biosystems
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.87
52 Haftanın En Yüksek Seviyesi	US$1.18
52 Haftanın En Düşük Seviyesi	US$0.58
Beta	1.12
11 Aylık Değişim	2.38%
3 Aylık Değişim	44.30%
1 Yıllık Değişim	-19.06%
33 Yıllık Değişim	-95.13%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-95.93%

Son Haberler & Güncellemeler

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Aug 03

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Jun 30

Recent updates

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Aug 03

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Jun 30

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Oct 10

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

May 09

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Mar 08

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Feb 07

Hissedar Getirileri

	RPID	US Life Sciences	US Pazar
7D	3.3%	-0.3%	-0.4%
1Y	-19.1%	17.6%	34.1%

Getiri vs. Endüstri: RPID geçen yıl % 17.6 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.

Getiri vs Piyasa: RPID geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is RPID's price volatile compared to industry and market?
RPID volatility
RPID Average Weekly Movement	8.8%
Life Sciences Industry Average Movement	8.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: RPID hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: RPID 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2006	193	Rob Spignesi	www.rapidmicrobio.com

Bir yaşam bilimleri teknolojisi şirketi olan Rapid Micro Biosystems, Inc. Amerika Birleşik Devletleri, Almanya, İsviçre, Japonya ve uluslararası alanda ilaç, tıbbi cihaz ve kişisel bakım ürünlerinin üretiminde mikrobiyal kontaminasyonun tespitine yönelik ürünler sunmaktadır. Şirket, Growth Direct sistemi, tescilli sarf malzemeleri, laboratuvar bilgi yönetim sistemi bağlantı yazılımı ve müşteri destek ve doğrulama hizmetlerini içeren Growth Direct platformunu sunmaktadır. Platform, biyolojikler, aşılar, hücre ve gen tedavileri ve steril enjektabllar gibi terapötik modaliteler için manuel mikrobiyal kalite kontrol (MQC) test iş akışlarını otomatikleştirmekte ve modernize etmektedir.

Rapid Micro Biosystems, Inc. Temel Bilgiler Özeti

Rapid Micro Biosystems'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
RPID temel i̇stati̇sti̇kler
Piyasa değeri	US$38.19m
Kazançlar(TTM)	-US$50.46m
Gelir(TTM)	US$24.71m

1.5x

P/S Oranı

-0.7x

F/K Oranı

RPID aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
RPID gelir tablosu (TTM)
Gelir	US$24.71m
Gelir Maliyeti	US$28.23m
Brüt Kâr	-US$3.51m
Diğer Giderler	US$46.95m
Kazançlar	-US$50.46m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.18
Brüt Marj	-14.22%
Net Kâr Marjı	-204.22%
Borç/Özkaynak Oranı	0%

RPID uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

RPID Stoklara Genel Bakış

Ödüller

Risk Analizi

Rapid Micro Biosystems, Inc. Rakipler

OTCPK:BIOQ

US$60.4m

NasdaqCM:CSBR

US$66.2m

NasdaqCM:BNGO

US$39.0m

NasdaqGS:ISO

US$30.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Independent Director recently bought US$50k worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Rapid Micro Biosystems, Inc. to Report Q2, 2024 Results on Aug 02, 2024

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Independent Director recently bought US$50k worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Rapid Micro Biosystems, Inc. to Report Q2, 2024 Results on Aug 02, 2024

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. to Report Q1, 2024 Results on May 03, 2024

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024

Rapid Micro Biosystems, Inc. to Report Fiscal Year 2023 Results on Mar 01, 2024

Rapid Micro Biosystems, Inc. Receives A Non-Compliance Notification Letter from the Nasdaq

Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023

Rapid Micro Biosystems, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Rapid Micro Biosystems Receives a Notification Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Rapid Micro Biosystems, Inc. Appoints of Kirk Malloy as Chair of Its Board of Directors

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Full Year of 2023

Consensus revenue estimates fall by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2022 Results on Mar 03, 2023

Rapid Micro Biosystems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Rapid Micro Biosystems, Inc. Announces Publication of Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$9.00

Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.71 loss in 3Q 2021)

Rapid Micro Biosystems, Inc. Reaffirms Full Year 2022 Revenue Outlook

Rapid Micro Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Rapid Micro Biosystems, Inc. Announces RMBnucleus Mold Alarm for the Growth Direct System

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Kennedy Lewis Capital Partners Master Fund II LP and Kennedy Lewis Capital Partners Master Fund III LP managed by Kennedy Lewis Investment Management LLC cancelled the acquisition of remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID).

Rapid Micro Biosystems, Inc. Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Rapid Micro Biosystems, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Kennedy Lewis Investment Management LLC delivered a Non-Binding Proposal to acquire remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID) for approximately $160 million.

Rapid Micro Biosystems, Inc.(NasdaqGS:RPID) dropped from Russell 2500 Value Index

Rapid Micro Biosystems, Inc. Reaffirms Earnings Guidance For Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2022

Alexander Schmitz Not to Stand for Reelection as Member of the Board of Directors of Rapid Micro Biosystems, Inc

Insider recently bought US$70k worth of stock

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance Full Year 2022

Full year 2021 earnings: Revenues in line with analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2021 Results on Mar 04, 2022

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Rapid Micro Biosystems Provides Revenue Guidance for the Full Year 2022

Third quarter 2021 earnings released: US$0.71 loss per share

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year of 2021

Rapid Micro Biosystems, Inc. has completed an IPO in the amount of $158.4 million.

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Rapid Micro Biosystems, Inc. Temel Bilgiler Özeti